Vestal Point Capital’s OnKure Therapeutics OKUR Stock Holding History

Vestal Point Capital’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.33M	Sell	1,825,699 -14,120	-0.8%	-$60.6K	0.19%	56
2026 Q1	$7.62M	Buy	1,839,819 +1,204,819	+190%	+$3.72M	0.21%	69
2025 Q4	$1.84M	Hold	635,000	–	–	0.06%	71
2025 Q3	$1.75M	Hold	635,000	–	–	0.08%	77
2025 Q2	$1.52M	Hold	635,000	–	–	0.08%	64
2025 Q1	$2.73M	Hold	635,000	–	–	0.2%	50
2024 Q4	$5.46M	Buy	635,000 +555,060	+694%	+$8.4M	0.32%	52
2024 Q3	$1.36M	Buy	79,940 +25,440	+47%	+$376K	0.1%	66
2024 Q2	$823K	Buy	54,500 +24,962	+85%	+$423K	0.06%	59
2024 Q1	$490K	Sell	29,538 -10,462	-26%	-$173K	0.04%	56
2023 Q4	$640K	Buy	+40,000	New	+$2.49M	0.07%	41

Other funds holding OKUR

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vestal Point Capital's OKUR Position: Q2 2026 in Review

Vestal Point Capital reduced its OnKure Therapeutics (OKUR) stake by 0.77% in Q2 2026, selling an estimated $60.6K and leaving 1,825,699 shares worth $8.33M. The position accounts for 0.19% of the portfolio, ranked #56.

Vestal Point Capital first reported a position in OKUR in Q4 2023 and has held it in 11 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

Vestal Point Capital held 1,825,699 shares of OnKure Therapeutics worth $8.33M as of Q2 2026.
Vestal Point Capital sold 14,120 OnKure Therapeutics shares in Q2 2026, an estimated $60.6K.
OnKure Therapeutics made up 0.19% of Vestal Point Capital's portfolio in Q2 2026, its #56 holding.
Vestal Point Capital first reported a position in OnKure Therapeutics in Q4 2023 and has held it in 11 quarters since.
75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.